Page last updated: 2024-08-21

cyclopentane and imatinib mesylate

cyclopentane has been researched along with imatinib mesylate in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Du, X; Jin, Y; Li, J; Li, Y; Liu, C; Lu, Y; Nie, D; Pan, J; Zhou, J	1
Bahjat, M; Bende, RJ; Bloedjes, T; de Wilde, G; Eldering, E; Guikema, JEJ; Kersten, MJ; Luijks, DM; Maas, C; van Dam, T; van Noesel, CJM	1

Other Studies

2 other study(ies) available for cyclopentane and imatinib mesylate

Article	Year
Antitumor Effects of Blocking Protein Neddylation in T315I-BCR-ABL Leukemia Cells and Leukemia Stem Cells. Cancer research, 2018, 03-15, Volume: 78, Issue:6 Topics: Animals; Antigens, CD34; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cyclopentanes; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Experimental; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice, Inbred C57BL; Molecular Targeted Therapy; Neoplastic Stem Cells; Point Mutation; Pyrimidines; Ubiquitin-Activating Enzymes	2018
The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors. Cell cycle (Georgetown, Tex.), 2019, Volume: 18, Issue:18 Topics: Apoptosis; Cell Line, Tumor; Cyclopentanes; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloid Cell Leukemia Sequence 1 Protein; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; S Phase Cell Cycle Checkpoints; Signal Transduction; Ubiquitin-Activating Enzymes	2019

Article

Year

Antitumor Effects of Blocking Protein Neddylation in T315I-BCR-ABL Leukemia Cells and Leukemia Stem Cells.

Cancer research, 2018, 03-15, Volume: 78, Issue:6

Topics: Animals; Antigens, CD34; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cyclopentanes; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Experimental; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice, Inbred C57BL; Molecular Targeted Therapy; Neoplastic Stem Cells; Point Mutation; Pyrimidines; Ubiquitin-Activating Enzymes

2018

The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors.

Cell cycle (Georgetown, Tex.), 2019, Volume: 18, Issue:18

Topics: Apoptosis; Cell Line, Tumor; Cyclopentanes; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloid Cell Leukemia Sequence 1 Protein; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; S Phase Cell Cycle Checkpoints; Signal Transduction; Ubiquitin-Activating Enzymes

2019